| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Chronic Myeloid Leukemia |
From the III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany (AF, MCM, PE, TL, MG, OF, WS, RH, AH); MLL Münchner Leukämielabor GmbH, München, Germany (CH)
Correspondence: Alice Fabarius, III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg, Wiesbadener Straße 7–11, 68305 Mannheim, Germany. E-mail: alice.fabarius{at}med3.ma.uniheidelberg.de
 |
ABSTRACT |
|---|
 TOP ABSTRACT Design and MethodsResults and DiscussionReferences |
|---|
Key words: chronic myeloid leukemia, cytogenetics, clonal evolution, tyrosine kinase inhibitors, dasatinib.
Chronic myeloid leukemia (CML) is a clonal hematologic disorder characterized by the translocation t(9;22) (q34;q11), resulting in the Philadelphia chromosome (Ph) and the bcr-abl fusion gene. This gene encodes a chimeric BCR-ABL fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype.1 The use of targeted therapies has significantly improved the treatment of CML. Imatinib (Glivec®), a selective inhibitor of the BCR-ABL tyrosine kinase achieved major or complete cytogenetic remissions (MCR or CCR) in 60% of CML patients who were intolerant or refractory to prior IFN therapy and up to 87% in newly diagnosed patients.2,3 But the accumulation of point mutations in the ABL kinase domain of BCR-ABL leading to clinical resistance to the drug has become a major problem.4 Clonal cytogenetic aberrations of the Ph positive hematopoiesis have been associated with the natural evolution of CML to advanced disease and also seem to play a role in imatinib resistance in CML patients. Clonal changes of Ph negative metaphases have been described after treatment with interferon alpha or imatinib in a minority of patients with cytogenetic response. Conflicting data suggest the selection of pre-existing clones indicating that residual Ph negative hematopoiesis co-exists with the malignant clone vs. induction of aneuploidy by tyrosine kinase inhibitors.5,6 Therefore, the prognostic impact of aberrations in the Ph negative hematopoiesis must still be clarified. Dasatinib (formerly BMS-354825) is an ATP-competitive dual SRC/ABL kinase inhibitor showing antiproliferative activity against hematologic tumor cell lines that can bind to both active and inactive conformations of the respective kinase domains. It is, therefore, effective against most imatinib-resistant forms of BCR-ABL. Inhibition of other SRC-family members and activity against c-KIT and PDGFRß were also demonstrated.7,8 The efficacy and safety of dasatinib has been demonstrated in patients with Ph positive CML after failure of imatinib therapy.9–11 However, little is known about the long-term efficacy and toxicity of dasatinib treatment. In contrast to patient treated with imatinib or IFN12 no clonal evolution in Ph positive cells and no clonal abnormalities in BCR-ABL negative cells are documented so far. This study, therefore, describes the effect of dasatinib on Ph positive clones with additional cytogenetic aberrations and the frequency of novel aberrations in Ph positive and Ph negative metaphases during therapy. In primary human cells dasatinib induced centrosome defects and delay of spindle formations.13 The influence on the hematopoietic cells of CML patients was, therefore, of major interest.
|
Design and Methods |
|---|
|
TOPABSTRACTDesign and MethodsResults and DiscussionReferences |
|---|
|
|
|
Results and Discussion |
|---|
|
TOPABSTRACTDesign and MethodsResults and DiscussionReferences |
|---|
Clonal chromosomal evolution
Novel aberrations of the Ph positive clone appeared during dasatinib treatment in six patients (8%) between one to 16 months after start of therapy including one case with t(3;22)(q21;q11), one with +idic(22)(p11) and two cases with +8. Two cases with two or more aberrations were observed (inv(3)(q21q26), monosomy 7 and i(17)(q10) in the first and +4,+12,+13,+21 in the second). In patients #22 and #23 the proportion of Ph positive cells with additional aberrations increased with time and patient #22 developed a myeloid BC under treatment. The remaining four patients showed no change or reduction of aberrant cells over time. No or only minor cytogenetic response was observed (Table 2). Time from diagnosis to dasatinib treatment was 81 months (range 22–124). Ph chromosome independent clonal evolution was identified in three patients (4%), two with major (patients #29 and #30) and one with complete cytogenetic response (patient #28) (Table 2). All patients showed trisomy 8 in the Ph negative metaphases and did not show any other chromosomal aberrations other than t(9;22).
Two Ph positive patients displayed trisomy 8 in Ph negative metaphases after imatinib failure prior to dasatinib treatment. No increase in Ph negative clones on dasatinib was observed after periods of four or 15 months treatment.
In total, 5 out of 71 patients (7%) showed clonal aberrations of Ph negative metaphases after consecutive imatinib/dasatinib therapies. None of these patients had morphological evidence for secondary neoplastic changes. After a median follow-up of nine months, four dasatinib treated patients showed resistance and three were intolerant to the drug. Six patients died during therapy, five of them in BC and one in CP after SCT.
In seventy-one dasatinib treated CML patients CCR of 37% and MCR of 10% were achieved after a median treatment duration of nine months. Dasatinib showed a benefit for patients resistant to or intolerant of a prior imatinib therapy.9–11 Moreover, dasatinib was efficacious in patients with clonal cytogenetic aberrations that concur with BCR-ABL independent imatinib resistance.
New additional chromosome aberrations in Ph positive metaphases were observed in six patients (8.5%). None of them achieved any cytogenetic response. The frequency of additional aberrations on dasatinib is comparable to those of patients treated with imatinib (9.3 %)12 and with untreated patients (8.8%).16 The observed abnormalities were common secondary changes frequently observed in CML during CP, AP, or BC after treatment with imatinib or IFN or even in untreated patients 12 and could be due to the natural history of the disease.
Furthermore, a significant minority of patients (4.2%) demonstrated novel aberrations in Ph negative cells on dasatinib treatment during the observation period. Three patients pre-treated with hydroxyurea, imatinib, and IFN up-front showed trisomy 8 in their Ph negative cells (patients #28, #29, and #30). The incidence is comparable to that after IFN or imatinib therapies (2–17%).5 Since clonal chromosome aberrations in Ph negative cells are mainly numerical, at least after imatinib treatment,17 these findings suggest a causative role of imatinib or dasatinib or prior chemotherapy in the emergence of clonal evolution or reflect genomic instability of the hematopoietic cells of CML patients. Ph negative evolution could also be due to selective pressure by imatinib or dasatinib on Ph positive clones, allowing pre-existing Ph negative clones to predominate. However, only a few cases with trisomy 8 in Ph positive and negative metaphases have been reported so far.18,19 In conclusion, dasatinib is efficient in patients resistant to or intolerant of imatinib. The incidence and quality of aberrations occurring in Ph positive cells during dasatinib treatment are comparable to those observed in clonal evolution during the natural course of CML or during treatment with other drugs. The prevalence of aberrations in Ph negative cells under dasatinib is low. Despite the inhibition of both ABL and SRC tyrosine kinases, no specific cytogenetic drug pattern for dasatinib could be detected and no secondary neoplastic diseases were observed after a short observation period.
Since numerical aberrations are frequent and recurrent in myeloid diseases, cytogenetic monitoring of patients with chromosomal changes in Ph negative cells is suggested.20
However, the wide variety of cases in regards to phases and types of disease, length of time from diagnosis to dasatinib treatment and short duration of dasatinib therapy allows only reduced valuation.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
AF: principal investigator with primary responsibility for the publication. CH, MCM, PE, TL, MG, OF, WS, RH and AH: contributed to the design of the study, to the work and to the interpretation of the results. All authors checked the final version of the manuscript.
The author reported no potential conflicts of interest.
Funding: this work was supported by the competence network ‘Acute and chronic leukemias’, sponsored by the German Bundesministerium für Bildung und Forschung (Projektträger Gesundheitsforschung; DLR e.V.) and Bristol-Myers Squibb, New York, NY.
Received for publication November 20, 2006. Accepted for publication April 12, 2007.
|
References |
|---|
|
TOPABSTRACTDesign and MethodsResults and DiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib Haematologica, August 1, 2008; 93(8): 1145 - 1154. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
